Skip to main content

Breast Cancer Clinical Trials

Review the breast cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 476-500 of 921

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in Patients with Breast Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Pembrolizumab in Treating Patients with Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
ARX788 for Treating Patients with HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: University of California San Francisco, San Francisco, California
Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin for the Treatment of Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Temporarily Closed to Accrual
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients with Advanced/Metastatic or Unresectable Solid Tumors with RAS Alterations and Triple Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
A Vaccine (H2NVAC) before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
mRNA-2752 with or without a PD1 Inhibitor in Treating Patients with High Grade Ductal Breast Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
Autologous Anti-NY-ESO-1 TCR-Engineered T Cells for the Treatment of Patients with Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
DNX-2440 for Resectable Colorectal Liver Metastasis
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
A Study to Examine Mindfulness Training to Improve Mental Health and Well-being in Younger Breast Cancer Survivors, HEAL-ABC Trial
Status: Active
Location: 299 locations
Comparing Single vs Multiple Doses of Radiation for Patients on Immunotherapy for Breast, Kidney, Small Cell Lung Cancer, Non-Small Cell Lung Cancer or Melanoma that Has Spread to the Brain, HYPOGRYPHE Study
Status: Active
Location: 35 locations
Distance-Based Exercise to Preserve Function and Prevent Disability (DEFEND)
Status: Active
Location: 17 locations
Fezolinetant for Reducing Vasomotor Symptoms in Women with Breast Cancer on Endocrine Therapy, FLASH-Breast Trial
Status: Active
Location: 12 locations
A Statin (Atorvastatin Calcium) for the Reduction of Cardiac Toxicity in Patients with Stage I-III Breast Cancer Receiving HER2 Targeted Therapy, STACIE Study
Status: Active
Location: 10 locations
An Unsupervised Exercise and Healthy Diet Intervention for the Improvement of Brain and Physical Health in Older Cancer Survivors and their Support Person, Vitality Trial
Status: Active
Location: 10 locations